The IPR&D charge is non-cash and does not affect cash flow or operations, but it will cause a large GAAP and Non-GAAP EPS miss vs prior guidance. Watch for the Q3 2026 earnings release and updated full-year guidance to assess whether underlying operational performance (revenue, enzyme therapy growth, VOXZOGO trends) remains on track.
Price Chart
Executive Summary
BioMarin disclosed that its Q3 2026 results will include ~$283M in pre-tax acquired IPR&D charges from the Alesta Therapeutics acquisition (closed Aug 31, 2026), with an unfavorable impact of ~$1.50 per share on both GAAP and Non-GAAP diluted EPS. Full-year 2026 charges are expected to total ~$320M, reducing EPS by ~$1.55. The company will provide updated 2026 guidance with Q3 results. This is a non-cash accounting charge that does not reflect operational deterioration, but the magnitude is material relative to prior EPS guidance.
Key Facts
- Alesta Therapeutics acquisition completed August 31, 2026
- Q3 2026 pre-tax IPR&D charge of ~$283 million
- Unfavorable impact of ~$1.50 to both GAAP and Non-GAAP diluted EPS for Q3 2026
- Full-year 2026 total pre-tax charges of ~$320 million
- Full-year EPS impact of ~$1.55 on both GAAP and Non-GAAP basis
- Prior full-year 2026 guidance (Aug 6, 2026) did not reflect Alesta acquisition
- Updated full-year 2026 guidance to be provided with Q3 2026 results
Financial Impact
~$283M pre-tax IPR&D charge in Q3 2026; ~$1.50 EPS impact in Q3; ~$1.55 EPS impact for full year 2026
Risk Factors
- Full-year 2026 EPS guidance will be revised downward materially from prior $4.85-$5.05 Non-GAAP range
- Acquisition integration costs and operating expenses may exceed disclosed estimates
- Q3 2026 results are preliminary and subject to change upon finalization
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001048477-26-000019 |
| Document: 0001048477-26-000019-index-headers.html | 0001048477-26-000019 |
| Document: 0001048477-26-000019-index.html | 0001048477-26-000019 |
| Document: 0001048477-26-000019.txt | 0001048477-26-000019 |
| 8-K Data (Synthetic) | 0001048477-26-000019 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $55.20 $55.14 | ▲ +0.11% | ▼ −0.87% | $55.75 (−1.00%) |
Sep 15, 2026 5w ago | 8-K | $64.45 $63.94 | ▼ −0.79% | ▼ −1.61% | $55.75 (−13.50%) |
Sep 14, 2026 6w ago | 8-K | $66.41 $64.06 | ▼ −3.54% | ▼ −3.65% | $55.75 (−16.05%) |
Sep 1, 2026 7w ago | 8-K | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $55.75 (−14.02%) |
Sep 1, 2026 7w ago | Press Release | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $55.75 (−14.02%) |
Aug 31, 2026 8w ago | 8-K | $65.23 $64.63 | ▼ −0.92% | ▼ −0.78% | $55.75 (−14.53%) |
Aug 18, 2026 9w ago | 8-K | $66.99 $66.12 | ▼ −1.30% | ▼ −1.10% | $55.75 (−16.78%) |
Jun 4, 2026 20w ago | 8-K | $56.77 $55.95 | ▼ −1.44% | ▼ −2.01% | $55.75 (−1.80%) |
Apr 27, 2026 26w ago | 8-K | $53.62 $55.42 | ▲ +3.36% | ▲ +2.96% | $55.75 (+3.96%) |
Apr 21, 2026 26w ago | DEFA14A | $54.16 $53.24 | ▼ −1.71% | ▼ −1.76% | $55.75 (+2.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers